Fujifilm Medical Systems is now offering digital breast tomosynthesis (DBT) as an optional software upgrade for its Aspire Cristalle digital mammography system, which has received U.S. FDA premarket approval.
“Receiving FDA approval for DBT is a momentous occasion for Fujifilm,” says Rob Fabrizio, Fujifilm’s director of strategic marketing, digital radiography and women’s health. “The unique dose savings and patient comfort innovations already available in the Aspire Cristalle full-field digital mammography (FFDM) system are now coupled with the new 3D imaging capabilities—an exciting advancement that U.S. providers have long been waiting for in their fight for early detection of breast cancer.”
Known as Amulet Innovality outside of the United States, Fujifilm’s optional DBT upgrade has been widely available in Europe, Asia, and Latin America since May 2013. The Aspire Cristalle FFDM system with DBT combines Fujifilm’s hexagonal close pattern detector design, advanced image processing, and image acquisition workflow to optimize patient dose while maximizing image quality.
With the DBT software option, the x-ray tube moves through an arc around the breast, acquiring a series of low-dose image slices at different angles; this produces a 3D view that allows radiologists to see through less-obstructed tissue. The acquired images are then reconstructed into a series of high-resolution 1 mm slices displayed individually or dynamically in a cine mode—making it easier to identify lesions that might be difficult to see in traditional 2D mammography images due to overlapping breast structures.
Fujifilm officials say this innovation will bring a new level of diagnostic confidence in screening—especially for women with dense breast tissue, who are more difficult to screen with traditional 2D technologies only.
For more information regarding this technology, visit Fujifilm Medical Systems.
